Canada · Delayed Price · Currency is CAD Cannara Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Gross cannabis revenue grew 16% year-over-year to CAD 44.1 million, with net income of CAD 4.8 million and adjusted EBITDA up 11%. Market share gains in Ontario and Alberta, strategic acquisitions, and a CAD 21 million Curaleaf deal support accelerated capacity expansion and international growth.
-
Operational scale and disciplined expansion have driven strong margins, consistent profitability, and market leadership in Quebec, with plans to double production and complete major CapEx projects by 2027. International opportunities are being explored, but Canadian growth remains the near-term focus.
-
Q2 saw revenue rise to CAD 27.2M with strong margins and market share gains, especially in Quebec, despite industry seasonality. Strategic investments, new product launches, and capacity expansion position the business for continued growth and international opportunities.
-
Disciplined growth, strong brand portfolio, and operational efficiency have driven rising market share and profitability, with a clear, capital-efficient expansion plan and robust financials. Strategic capital raises and TSX uplisting aim to enhance liquidity and investor access.
-
Record Q1 2026 results with 20% net revenue growth year-over-year, 45% gross margin, and strong cash flow. Market share leadership in Quebec and national gains driven by premium product launches and disciplined expansion.
Fiscal Year 2025
-
Fiscal 2025 set new records in revenue, profit, and cash flow, driven by expanded capacity and operational efficiency. Market share surged across key provinces, with leadership in several product categories. Continued growth and margin improvement are expected as further expansion comes online.
-
The company operates two major Quebec facilities, achieving profitability and strong free cash flow, with a scalable production model and a focus on proprietary genetics and brand loyalty. Financial performance is robust, with 44% gross margins and steady reinvestment into growth. Upcoming vape launches in Quebec are expected to further boost revenue.
-
Cannabis producer achieved record financial results in 2025, with strong revenue, margin, and cash flow growth driven by operational discipline, vertical integration, and product innovation. Expansion plans leverage existing assets and Quebec's cost advantages, while market share and brand leadership continue to rise.
-
Q3 2025 delivered record revenue, profit, and cash flow, driven by operational breakthroughs and expanded capacity. Quebec market share surged, and national share grew despite competitive pressures. Focus remains on disciplined expansion, margin leadership, and innovation.
-
A vertically integrated cannabis producer is rapidly expanding capacity and market share, especially in Quebec, while maintaining strong financial performance and margins. Strategic investments in genetics, operational efficiency, and brand leadership drive growth, with expansion funded by internal cash flow and debt.
-
Record Q2 results with 35% year-over-year revenue growth, industry-leading margins, and expanding market share in key categories. Capacity is scaling to meet demand, with a focus on Canadian market leadership and high ROI investments.
Fiscal Year 2024
-
Achieved strong fiscal 2024 results with 43% revenue growth, positive EBITDA, and rising market share. Expansion plans target 100,000 kg annual capacity and 10% national market share, driven by brand leadership, innovation, and operational efficiency.
-
Q3 2024 saw revenue of CAD 19.5M and net income of CAD 2M, with strong market share gains in Quebec and a focus on scaling production and sales nationally. Strategic cost advantages and product innovation underpin growth, while capital allocation prioritizes reinvestment and debt reduction.